News & Analysis

Real estate returns at CalSTRS fall short of the mark…(2)

The second largest US pension plan said returns for real estate during fiscal year 2011-2012 fell short of an industry benchmark and were down from a 17.5 percent return the previous year.

Real estate returns at CalSTRS fall short of the mark…

The second largest US pension plan said returns for real estate during fiscal year 2011-2012 fell short of an industry benchmark and were down from a 17.5 percent return the previous year.

TPG inks $1.9bn pharma take-private(2)

The firm's buyout group will acquire listed pharmaceutical company Par Pharmaceutical. TPG also has investments in several pharmaceutical companies through its TPG Biotech portfolio.

TPG inks $1.9bn pharma take-private

The firm's buyout group will acquire listed pharmaceutical company Par Pharmaceutical. TPG also has investments in several pharmaceutical companies through its TPG Biotech portfolio.

CalSTRS' lacklustre year buoyed by PE

The retirement system’s $21bn private equity portfolio generated a 5.9% return last fiscal year, outperforming its overall portfolio by 4.1%.

India outlook negative says Fitch(3)

The number of Indian infrastructure projects given a negative rating by the agency is on the increase as macroeconomic challenges and factors specific to the industry take their toll. Government action and sector reforms are among measures cited that could help address the problems.

India outlook negative says Fitch(2)

The number of Indian infrastructure projects given a negative rating by the agency is on the increase as macroeconomic challenges and factors specific to the industry take their toll. Government action and sector reforms are among measures cited that could help address the problems.

India outlook negative says Fitch

The number of Indian infrastructure projects given a negative rating by the agency is on the increase as macroeconomic challenges and factors specific to the industry take their toll. Government action and sector reforms are among measures cited that could help address the problems.

TPG inks $1.9bn pharma take-private(3)

The firm's buyout group will acquire listed pharmaceutical company Par Pharmaceutical. TPG also has investments in several pharmaceutical companies through its TPG Biotech portfolio.

GPs turn to dividend recaps(2)

There has been a pronounced increase in the number of dividend recapitalisations as firms seek alternative means to realise value from their investments, according to a Moody’s report.